. U.S. Serial No.: 09/896,856

Amdt. Dated November 24, 2003

Response to Final Office Action mailed on May 23, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in

the application:

Listing of Claims:

A listing of the claims follows. Claims 31, 33, 41, and 42 are amended as

follows, wherein strikeout in brackets [00] indicates deleted terminology and underling

[00] indicates added terminology.

Claims 1-30 (canceled)

31. (Twice Amended) A method of increasing survival of a motor neuron, comprising

administering directly to a motor neuron [a survival-promoting amount of] an isolated

[biologically active] polypeptide exhibiting neurotrophic activity and having an amino

acid sequence identity of at least 70% to SEQ ID NO: 3 or SEQ ID NO:8, but not a rat

cardiotrophin-1.

32. (canceled) Please cancel claim 32 without prejudice to later prosecution.

33. (Amended) The method of claim [32] 31, wherein the motor neuron is a ciliary

ganglion.

34. (Canceled) Please cancel claim 34 without prejudice to later prosecution.

Claims 35-40 (canceled)

Patent Docket P0894P1D2C4

U.S. Serial No.: 09/896,856 Amdt. Dated November 24, 2003

Response to Final Office Action mailed on May 23, 2003

41. (Twice Amended) The method of claim 31 further comprising administering a [therapeutically effective amount of a] second neurotrophic factor for increasing neuronal survival.

42. (Twice Amended) The method of claim [39]41, wherein the second neurotrophic factor is selected from the group consisting of IGF-1, CNTF, NGF, BDNF, NT-3, and NT-4.